Drugs for Multiple Endocrine Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 48)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Dexlansoprazole |
Approved, Investigational |
Phase 4 |
|
138530-94-6 |
9578005 |
Synonyms:
(+)-LANSOPRAZOL
(R)-LANSOPRAZOLE
2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
DEXILANT
DEXILANT SOLUTAB
DEXLANSOPRAZOLE
KAPIDEX
|
LANSOPRAZOLE R-FORM
R-lansoprazole
T 168390
T-168390
TAK 390
TAK-390
|
|
2 |
|
Lansoprazole |
Approved, Investigational |
Phase 4 |
|
103577-45-3 |
3883 |
Synonyms:
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
A-65006
Abbot brand OF lansoprazole
AG 1749
AG-1749
Agopton
Almirall brand OF lansoprazole
Amarin
Aprazol
Bamalite
Biuret
Biuret Gr
Biuret Reagent
Biuret Reagent Solution
Blason
Compraz
Dakar
Hoechst brand OF lansoprazole
Hormona brand OF lansoprazole
Ilsatec
Ketian
Lancid
Lanfast
Lanproton
Lansol
Lansopep
Lansophed
Lansoprazol
Lansoprazol [INN-Spanish]
LANSOPRAZOLE
Lansoprazole [Usan:Ban:Inn]
Lansoprazole abbot brand
Lansoprazole almirall brand
Lansoprazole hoechst brand
Lansoprazole hormona brand
Lansoprazole lederle brand
Lansoprazole promeco brand
Lansoprazole salvar brand
Lansoprazole sodium
Lansoprazole takeda brand
Lansoprazole tap brand
Lansoprazole tecnobio brand
Lansoprazole vinas brand
Lansoprazole wyeth brand
Lansoprazoles
Lansoprazolum
|
Lansoprazolum [INN-Latin]
Lansox
Lanston
Lanz
Lanzo
Lanzol
Lanzol-30
Lanzopral
Lanzor
Lanzul
Lapraz
Lasoprol
Lederle brand OF lansoprazole
Limpidex
Linamarin
Mesactol
Monolitum
Ogast
Ogastro
Opiren
Prevacid
PREVACID (TN)
PREVACID 24HR
PREVACID DELAYED RELEASE
PREVACID IV
PREVACID SOLUTAB
Prevpac
Prezal
Pro ulco
Promeco
promeco Brand OF lansoprazole
Promp
Prosogan
Salvar brand OF lansoprazole
Sodium, lansoprazole
Suprecid
Takeda brand OF lansoprazole
Takepron
TAP brand OF lansoprazole
tecnobio Brand OF lansoprazole
Ulpax
Vinas brand OF lansoprazole
Wyeth brand OF lansoprazole
Zoprol
Zoton
|
|
3 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
4 |
|
Anti-Ulcer Agents |
|
Phase 4 |
|
|
|
5 |
|
Antacids |
|
Phase 4 |
|
|
|
6 |
|
Proton Pump Inhibitors |
|
Phase 4 |
|
|
|
7 |
|
Somatostatin |
Approved, Investigational |
Phase 3 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
8 |
|
Hormones |
|
Phase 3 |
|
|
|
9 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
10 |
|
Aflibercept |
Approved |
Phase 2 |
|
862111-32-8 |
124490314 |
Synonyms:
AFLIBERCEPT
AFLIBERCEPT (GENETICAL RECOMBINATION)
AVE0005
AVE-0005
BAY86-5321
BAY-865321
|
BAY-86-5321
EYLEA
VEGF TRAP
VEGF TRAP-EYE
ZALTRAP
ZIV-AFLIBERCEPT
|
|
11 |
|
Octreotide |
Approved, Investigational |
Phase 2 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
12 |
|
Parathyroid hormone |
Approved, Investigational |
Phase 2 |
|
9002-64-6 |
|
Synonyms:
ALX1-11
ALX-111
ALX-1-11
NPSP558
NPSP-558
Parathormone
Parathormone (human recombinant)
Parathyrin
PARATHYROID HORMONE
Parathyroid hormone (1-84) human recombinant
|
Parathyroid hormone (rDNA)
PAROIDIN
PREOTACT
PTH
PTH(1-84)
rhPTH
rhPTH(1-84)
rPTH
rPTH(1-84)
|
|
13 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
14 |
|
Lenvatinib |
Approved, Investigational |
Phase 2 |
|
417716-92-8 |
9823820 |
Synonyms:
4-(3-chloro-4-((Cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
4-(3-Chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
e 7080
E 7080|ER-203492-00|Kisplyx®|Lenvima®
e7080
E-7080
|
ER-203492-00
KISPLYX
LENVATINIB
LENVATINIB MESYLATE
Lenvima
UNII-ee083865g2
|
|
15 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
16 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
17 |
|
Erlotinib |
Approved, Investigational |
Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
18 |
|
Pertuzumab |
Approved |
Phase 2 |
|
380610-27-5 |
|
Synonyms:
2C4 ANTIBODY
2C4|Omnitarg® (obsolete trade name)|Perjeta®
Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
LS-185920
MOAB 2C4
MONOCLONAL ANTIBODY 2C4
|
OMNITARG
OMNITARG PERJETA
PERJETA
PERTUZUMAB
RG-1273
RHUMAB-2C4
|
|
19 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
20 |
|
Endothelial Growth Factors |
|
Phase 2 |
|
|
|
21 |
|
Mitogens |
|
Phase 2 |
|
|
|
22 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2 |
|
|
|
23 |
|
Dihydroxyphenylalanine |
|
Phase 2 |
|
|
|
24 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
25 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
26 |
|
Immunoglobulins, Intravenous |
|
Phase 1 |
|
|
|
27 |
|
Immunoglobulins |
|
Phase 1 |
|
|
|
28 |
|
Antibodies |
|
Phase 1 |
|
|
|
29 |
|
gamma-Globulins |
|
Phase 1 |
|
|
|
30 |
|
Rho(D) Immune Globulin |
|
Phase 1 |
|
|
|
31 |
|
Vancomycin |
Approved |
|
|
1404-90-6 |
14969 |
Synonyms:
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(2.2SP,3.5SA,2.6SP)-O(4.2),C(3.4)
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-beta-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-beta-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-b-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-b-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-β-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-β-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
Abbott brand OF vancomycin hydrochloride
AB-vancomycin
Azupharma brand OF vancomycin hydrochloride
C(5.4),O(4.6)
Cell pharm brand OF vancomycin hydrochloride
Chiesi brand OF vancomycin hydrochloride
Combino brand OF vancomycin hydrochloride
Curasan brand OF vancomycin hydrochloride
Dakota brand OF vancomycin hydrochloride
Diatracin
Dista brand OF vancomycin hydrochloride
Eli lilly brand OF vancomycin hydrochloride
Hexal brand OF vancomycin hydrochloride
Hydrochloride, vancomycin
Lilly brand OF vancomycin hydrochloride
MIP brand OF vancomycin hydrochloride
Norman brand OF vancomycin hydrochloride
Ratiopharm brand OF vancomycin hydrochloride
|
Sulfate, vancomycin
Vanco azupharma
Vanco-cell
Vancocin
Vancocin HCL
Vancocine
VANCOLED
Vancomicin
Vancomicina
Vancomicina abbott
Vancomicina chiesi
Vancomicina combino phar
Vancomicina norman
VANCOMYCIN
Vancomycin HCL
Vancomycin hexal
Vancomycin hydrochloride
Vancomycin lilly
Vancomycin phosphate (1:2)
Vancomycin phosphate (1:2), decahydrate
Vancomycin sulfate
Vancomycine
Vancomycine dakota
Vancomycin-ratiopharm
Vancomycinum
VANCOR
Vanco-saar
|
|
32 |
|
Histamine |
Approved, Investigational |
|
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Î’-imidazolyl-4-ethylamine
|
|
33 |
|
Morphine |
Approved, Investigational |
|
|
57-27-2 |
5288826 |
Synonyms:
(-)-Heroin hydrochloride
(-)-Morphine
(−)-MORPHINE
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5Α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5Α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
ANHYDROUS MORPHINE
Apokyn
Astramorph PF
AVINZA
Chloride, morphine
Contin, MS
D-(-)-Morphine
DEPODUR
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dulcontin
Duramorph
Duramorph PF
Duromorph
Epimorph
Heroin hydrochloride
Heroine hydrochloride
IDS-NM-009
INFUMORPH
KADIAN
l-Morphine
M.O.S
Meconium
M-Eslon
Morfina
Morfina dosa
|
Morphia
Morphin
Morphina
MORPHINE
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
morphine sulfate|Ms Contin®|Oramorph®
Morphinism
Morphinum
Morphitec
Morphium
Moscontin
MS Contin
MS/L
MS/S
MSIR
N02AA01
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
ORAMORPH
Oramorph SR
Ospalivina
Rescudose
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
Statex
Statex Drops
Substitol
Sulfate, morphine
|
|
34 |
|
Ethanol |
Approved |
|
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
35 |
|
Polidocanol |
Approved |
|
|
9002-92-0 |
78933 |
Synonyms:
Aethoxy-sklerol
ASCLERA
C-12-e-4
DODECYL nona ethylene glycol ether
Dodecyl nonaoxyethylene ether
Dodecyl tetra(oxyethylene) ether
Dodecylnonaoxyethylene glycol monoether
Dodecyltetraethylene glycol monoether
Dodecyl-tetraethyleneoxide ether
Laureth 9
|
Laureth-9
Macrogol 9 lauryl ether
Nonaethylene glycol monododecyl ether
Nonaethylene glycol monolauryl ether
PEG-9 lauryl ether
Polidocanol
Polydocanol
Polyethylene glycol 450 lauryl ether
Polyoxyl 9 lauryl ether
VARITHENA
|
|
36 |
|
Salmon calcitonin |
Approved, Investigational |
|
|
47931-85-1 |
155817456 |
Synonyms:
CALCITONIN (SALMON SYNTHETIC)
Calcitonin salmon
CALCITONIN SALMON RECOMBINANT
Calcitonin, salmon
Calcitonina salmón sintética
|
Calcitonin-salmon
CT (salmon)|Miacalcin®
FORTICAL
Recombinant salmon calcitonin
Salmon calcitonin
|
|
37 |
|
Leflunomide |
Approved, Investigational |
|
|
75706-12-6 |
3899 |
Synonyms:
5-Methylisoxazole-4-carboxylate (4-trifluoromethyl)anilide
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
a,a,a-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
ARABLOC
Arabloc®|Arava®|HWA 486|HWA-486|lefunamide|SU-101
Arava
Aventis behring brand OF leflunomide
Aventis brand OF leflunomide
Aventis pharma brand OF leflunomide
Hoechst brand OF leflunomide
HWA 486
HWA-486
|
L04AA13
Leflunomida
LEFLUNOMIDE
Léflunomide
Leflunomidum
Leflunomidum [INN-Latin]
LEFUNAMIDE
LEFUNOMIDE
Lefunomide [INN-Spanish]
N-(4-Trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
SU101
SU-101
SULOL
Α,α,α-trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
|
|
38 |
|
D-Phenylalanine |
Approved, Experimental, Investigational, Nutraceutical |
Early Phase 1 |
|
63-91-2, 673-06-3 |
6140 71567 |
Synonyms:
(-)-beta-Phenylalanine
(6S)-Tetrahydrofolate
(6S)-Tetrahydrofolic acid
(6S)-THFA
(L)-Phenylalanine
(S)-(-)-Phenylalanine
(S)-2-Amino-3-phenylpropanoate
(S)-2-Amino-3-phenylpropanoic acid
(S)-2-Amino-3-phenylpropionate
(S)-2-AMINO-3-PHENYLPROPIONIC ACID
(S)-a-Amino-b-phenylpropionate
(S)-a-Amino-b-phenylpropionic acid
(S)-alpha-Aminobenzenepropanoate
(S)-alpha-Amino-benzenepropanoate
(S)-alpha-Aminobenzenepropanoic acid
(S)-alpha-Amino-benzenepropanoic acid
(S)-alpha-Amino-beta-phenylpropionate
(S)-ALPHA-AMINO-BETA-PHENYLPROPIONIC ACID
(S)-alpha-Aminohydrocinnamate
(S)-alpha-Aminohydrocinnamic acid
(S)-Phenylalanine
(S)-Α-amino-β-phenylpropionate
(S)-Α-amino-β-phenylpropionic acid
3-PHENYL-L-ALANINE
5,6,7,8-Tetrahydrofolate
5,6,7,8-Tetrahydrofolic acid
a-Amino-b-phenylpropionate
a-Amino-b-phenylpropionic acid
alpha-Amino-beta-phenylpropionate
alpha-Amino-beta-phenylpropionic acid
alpha-Aminohydrocinnamate
|
alpha-Aminohydrocinnamic acid
beta-Phenylalanine
beta-Phenyl-alpha-alanine
BETA-PHENYL-L-ALANINE
b-Phenyl-L-alanine
D-(+)-phenylalanine
DL-Phenylalanine
Endorphenyl
F
FEMA NO. 3585
Fenilalanina
L-2-Amino-3-phenylpropionate
L-2-Amino-3-phenylpropionic acid
L-Isomer phenylalanine
L-PHE
L-Phenylalanine
NSC-79477
PHE
Phenylalamine
Phenylalanin
Phenylalanine
Phenyl-alanine
Phenylalanine, L isomer
Phenylalanine, L-isomer
Phenylalaninum
Tetrahydrofolate
THF
Α-amino-β-phenylpropionate
Α-amino-β-phenylpropionic acid
Î’-PHENYL-L-ALANINE
|
|
39 |
|
Calcitonin gene-related peptide |
Investigational |
|
|
83652-28-2 |
91976570 |
Synonyms:
2-{[2-({6-amino-2-[(2-{[2-({2-[(2-{[2-({[1-(2-{[2-({2-[(2-{[6-amino-2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[({19-[(2-amino-1-hydroxypropylidene)amino]-16-(carboxymethyl)-6,9,12,15,18-pentahydroxy-7,13-bis(1-hydroxyethyl)-10-methyl-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-4-yl}(hydroxy)methylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(1H-imidazol-5-yl)propylidene)amino]-5-carbamimidamido-1-hydroxypentylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-4-methylpentylidene)amino]-1,3-dihydroxypropylidene}amino)-5-carbamimidamido-1-hydroxypentylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxy-3-methylbutylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxyhexylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene)amino]-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene}amino)-1-hydroxy-3-phenylpropylidene]amino}-3-methylbutanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxyethylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyhexylidene}amino)-1-hydroxypropylidene]amino}-3-phenylpropanoate
Calcitonin gene related peptide
Calcitonin-gene-related peptide
|
|
|
40 |
|
Histamine phosphate |
|
|
|
51-74-1 |
134614 |
Synonyms:
2)
4-(2-AMINOETHYL)IMIDAZOLE BIS(DIHYDROGEN PHOSPHATE)
4-(2-AMINOETHYL)IMIDAZOLE DI-ACID PHOSPHATE
HISTAMINE ACID PHOSPHATE
|
HISTAMINE BIPHOSPHATE
HISTAMINE DIHYDROGEN PHOSPHATE
HISTAMINE DIPHOSPHATE
HISTAMINE PHOSPHATE (1
|
|
41 |
|
Calcium, Dietary |
|
|
|
|
|
42 |
|
Calcitonin |
|
|
|
|
|
Synonyms:
4-{[1-({1-[(5-amino-1-{[1-({1-[(1-{[1-(2-{[4-carbamimidamido-1-({2-hydroxy-1-[(1-{[2-hydroxy-1-({[(2-hydroxy-1-{[({3-hydroxy-1-[2-(C-hydroxycarbonimidoyl)pyrrolidin-1-yl]-1-oxobutan-2-yl}-C-hydroxycarbonimidoyl)methyl]-C-hydroxycarbonimidoyl}ethyl)-C-hydroxycarbonimidoyl]methyl}-C-hydroxycarbonimidoyl)propyl]-C-hydroxycarbonimidoyl}-2-(C-hydroxycarbonimidoyl)ethyl)-C-hydroxycarbonimidoyl]propyl}-C-hydroxycarbonimidoyl)butyl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-C-hydroxycarbonimidoyl}-2-hydroxypropyl)-C-hydroxycarbonimidoyl]-3-(C-hydroxycarbonimidoyl)propyl}-C-hydroxycarbonimidoyl)-3-methylbutyl]-C-hydroxycarbonimidoyl}pentyl)-C-hydroxycarbonimidoyl]-2-(1H-imidazol-5-yl)ethyl}-C-hydroxycarbonimidoyl)-3-methylbutyl]-C-hydroxycarbonimidoyl}-4-({2-[(2-{[2-({6-amino-2-[(2-{[2-({2-[({22-amino-6,9,12,15,18,21-hexahydroxy-16-[(C-hydroxycarbonimidoyl)methyl]-7-(1-hydroxyethyl)-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosa-5,8,11,14,17,20-hexaen-4-yl}(hydroxy)methylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxyhexylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene}amino)butanoate
Calcihexal
Calcimar
CALCITARE
CALCITONIN
Calcitonin salmon
CALSYNAR
Cibacalcin
Forcaltonin
|
Fortical
Miacalcic
Miacalcin
Recombinant salmon calcitonin
Salcatonin
Salmon calcitonin
Salmon calcitonin (1-32)
Synthetic salmon calcitonin
|
|
43 |
|
Katacalcin |
|
|
|
|
16172926 |
44 |
|
Immunosuppressive Agents |
|
|
|
|
|
45 |
|
Immunologic Factors |
|
|
|
|
|
46 |
|
Radiopharmaceuticals |
|
Early Phase 1 |
|
|
|
47 |
|
Edotreotide |
|
Early Phase 1 |
|
|
23724894 |
Synonyms:
2-(4-{[(1-{[10-(4-aminobutyl)-4-[(1,3-dihydroxybutan-2-yl)-C-hydroxycarbonimidoyl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-19-yl]-C-hydroxycarbonimidoyl}-2-phenylethyl)-C-hydroxycarbonimidoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetate
|
DOTA-Tyr<sup>3</sup>-octreotide|DOTA<sup>0</sup>-Phe<sup>1</sup>-Tyr<sup>3</sup>-octreotide|Ga-DOTA-TOC|Ga-DOTATOC|SMT487|SomaKit TOC®
|
|
48 |
|
Calcium |
Nutraceutical |
|
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
Interventional clinical trials:
(show all 35)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors |
Completed |
NCT00204373 |
Phase 4 |
Lansoprazole (Prevacid) |
2 |
Non-functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Treated With Somatostatin Analogs (SA) Versus NO Treatment - a Prospective, Randomized, Controlled Multicenter Study |
Not yet recruiting |
NCT02705651 |
Phase 3 |
Somatostatin-Analog |
3 |
Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma |
Completed |
NCT00514046 |
Phase 1, Phase 2 |
Vandetanib |
4 |
Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors |
Completed |
NCT02101918 |
Phase 2 |
|
5 |
A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma |
Completed |
NCT00454363 |
Phase 2 |
Pazopanib Hydrochloride |
6 |
Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study |
Completed |
NCT00990535 |
Phase 2 |
Octreotide-LAR |
7 |
Studies of Hyperparathyroidism and Related Disorders |
Completed |
NCT00001277 |
Phase 2 |
68Ga-Dotatate;18F-DOPA |
8 |
A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMAâ„¢ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer |
Completed |
NCT00358956 |
Phase 2 |
ZD6474 (vandetanib) |
9 |
A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid Tumors |
Recruiting |
NCT03950609 |
Phase 2 |
Everolimus;Lenvatinib |
10 |
Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma |
Active, not recruiting |
NCT00390325 |
Phase 2 |
Sorafenib Tosylate |
11 |
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors |
Terminated |
NCT00947167 |
Phase 2 |
pertuzumab;erlotinib |
12 |
The Efficacy of High-Dose Intravenous Immunoglobulin Therapy in Patients With Stiff-Man Syndrome: A Double-Blind, Placebo-Controlled Trial |
Completed |
NCT00001550 |
Phase 1 |
IVIg |
13 |
A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors |
Withdrawn |
NCT02831179 |
Phase 1 |
Capecitabine;Temozolomide;Veliparib |
14 |
Type 1 Multiple Endocrine Neoplasia : a Cohort Study of the Endocrine Tumor Study Group (GTE) |
Unknown status |
NCT03262129 |
|
|
15 |
Revisiting the Evidence for Routine Transcervical Thymectomy for the Prevention of Thymic Carcinoid Tumours in MEN-1 Patients a Case Series |
Completed |
NCT05061784 |
|
|
16 |
Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients |
Completed |
NCT01424878 |
|
|
17 |
Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes |
Completed |
NCT00501449 |
|
|
18 |
Genetic Polymorphisms Associated With Histamine Disposition in Children With Vancomycin Associated Red Man Syndrome (RMS) |
Completed |
NCT00824122 |
|
|
19 |
A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers |
Completed |
NCT01794676 |
|
|
20 |
Coordination of Rare Diseases at Sanford |
Recruiting |
NCT01793168 |
|
|
21 |
Familial Investigations of Childhood Cancer Predisposition |
Recruiting |
NCT03050268 |
|
|
22 |
Study and Follow-up of Multiple Endocrine Neoplasia Type 1 |
Recruiting |
NCT03348501 |
|
|
23 |
Endoscopic Ultrasound-guided Fine-needle Injection for Multiple Endocrine Neoplasia Type 1-related Pancreatic Neuroendocrine Tumors: a Prospective Multicenter Study |
Recruiting |
NCT05554744 |
|
|
24 |
Study and Monitoring of Multiple Endocrine Neoplasia Type 1 |
Recruiting |
NCT03966612 |
|
|
25 |
PRIME Study: Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients |
Recruiting |
NCT05037461 |
|
|
26 |
Natural History Study of Parathyroid Disorders |
Recruiting |
NCT04969926 |
|
|
27 |
Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Patients |
Recruiting |
NCT03048266 |
|
|
28 |
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) |
Recruiting |
NCT03053999 |
|
|
29 |
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) |
Recruiting |
NCT04028479 |
|
Systemic Treatment (T) |
30 |
Genetic Modifying Factors and Pheochromocytomas in Multiple Endocrine Neoplasia Type 2 |
Recruiting |
NCT05158712 |
|
|
31 |
Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 |
Active, not recruiting |
NCT03048279 |
|
|
32 |
Family Studies in Metabolic Diseases and Mineral Metabolism |
Active, not recruiting |
NCT00001345 |
|
|
33 |
Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) |
Active, not recruiting |
NCT03043508 |
|
|
34 |
Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial |
Not yet recruiting |
NCT05605587 |
|
Leflunomide 20 mg |
35 |
An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC |
Terminated |
NCT03001349 |
Early Phase 1 |
Gallium Ga 68-Edotreotide |
|